Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

ReTenTion Next Generation Immune Checkpoint Inhibitor for Cancer Therapy

Coordinator
Vrije Universiteit Brussel, Belgium
Runs
15 February 2026 to 14 February 2028
Status
Running
EU funding
€216k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101205497

What the project is doing

In the project's own words, from its summary on CORDIS.

Immune checkpoint inhibitors (ICIs) for cancer therapy have revolutionized the treatment of several cancers. These ICIs are made from monoclonal antibodies that antagonize inhibitory signals via cytotoxic T-lymphocyte- associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) that block the tumoricidal activity of T cells. Although these ICIs have improved the overall survival of cancer patients such as cutaneous melanoma patients, only one third of patients has remained progression-free 5 years after initiating ICI therapy.

This low efficacy is largely due to (1) the presence of immune suppressive regulatory T cells (Treg) within tumor microenvironment (TME) (2) the lack of efficacy of tumor penetration and retention. To improve the current ICI, this project RenTenTion aims to develop a next generation ICIs with smaller molecule so called single domain antibody (sdAb), give rise to enhanced tumor penetration. Targeting against a new immune checkpoint molecule 41-BB that highly expressed by intratumoral Treg, this next generation sdAb based ICI will inhibit tumor promoting immune cells Treg, while stimulate tumor rejecting immune cells such as effector T cells in tumors.

Additionally, this project will couple the sdAb with collagen binding domain receptor so called leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) that bind to collagen in the tumor, therefore sustain tumor retention. This project “ReTenTion” will fill a gap for a strong need for new ICI molecules capable of addressing immunosuppressive in TME, yet smaller than conventional ICIs, boosting passive delivery.

Topics

Who is involved

OrganisationCityCountryRole
Vrije Universiteit BrusselBruxelles / BrusselBelgiumCoordinator
Etherna ImmunotherapiesNielBelgiumAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI